Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. METHODS: In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary end point was the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population. RESULTS: A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo). Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group. Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate. CONCLUSIONS: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adults with overweight or obesity, plus at least one weight-related coexisting condition, but without type 2 diabetes, the maximum reduction in weight at week 72 was 11•2% with orforglipron 36 mg/day versus 2•1 % with placebo.130”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [130]
In the citing paper
“Orforglipron 6-36 mg once daily vs placebo over 72 weeks Up to 9•1% (8•1-10•1) Up to 0•3% (several doses; SEM 0•0%) High drug discontinuation rate (up to 24%), up to 7% due to gastrointestinal adverse events; weight plateau reached after ~52 weeks Wharton et al (2025) 130”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [130]
In the citing paper
“Notably, a substantial proportion of participants achieved ≥10% weight loss, a threshold associated with meaningful metabolic improvements and cardiovascular risk reduction.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [46]
In the citing paper
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [46]
In the citing paper
“In the phase 3 ATTAIN-1 trial, it produced up to 11.2% WL with the highest dose of 36 mg daily in individuals without T2DM [142].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [142]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Self-citationWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
A new framework for the diagnosis, staging and management of obesity in adults
Busetto, L., Dicker, D., Frühbeck, G., Halford, J. C. G., Sbraccia, P., Yumuk, V., & Goossens, G. H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03095-3 · Cited by 501
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Self-citationKnop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Research works printed but not linked: 2
- Wu Q, Du Y, Ahmad N, et al. Sex differences in body weight reduction achieved with incretin-based therapies: a meta-analysis. Poster abstracts. Obesity (Silver Spring) 2024;32:Suppl 1:5-308.39562472
- Pfizer provides update on oral GLP-1 receptor agonist danuglipron. News release of Pfizer New York April 14 2025 (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist).
Cited by
Items 101–167 of 167
Monami, M., Bertoli, S., Ciudin, A., McGowan, B. M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70956 · Cited by 1
Self-citationAndréelli, F. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.005
Pharmacotherapy in childhood obesity: Key points from the 2023 AAP clinical practice guideline
Alam, F., & Newbern, D. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151608
Garvey, W. T., Rosenstock, J., Bays, H. E., Denham, D. S., Kohli, A., Haines, M., Jones, C., Kwan, E., CASTELLOE, E. N., Marmon, T., et al. (2026) · Obesity · doi:10.1002/oby.70271
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Mohamed, M. R., Abdallfatah, A., Elsekhary, A., El‐Nemr, A. F., Eladawi, S., Maihoub, O., Abdulhay, H., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70275
Beyond Weight Loss: The Challenge of Stopping Obesity Management Medications
Kermansaravi, M., & COHEN, R. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71317 · Cited by 1
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2610-3294
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Finding Common Ground: Updates from ObesityWeek 2025
Millard, A. J. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.04.005
Shifting the goalposts in obesity drug development
Garvey, W. T. (2026) · Nature Medicine · doi:10.1038/s41591-026-04462-y
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Díaz, L. A. H., Alanis, B. A. L., Zorrilla-Núñez, L. F., & Muñoz-Maldonado, G. E. (2026) · Cureus · doi:10.7759/cureus.113460
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108365 · Cited by 1
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Arbogast, M., Bayer, M., Biraima, M., Brunner, W., Rabl, C., Gerber, P., & Gerö, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100742
Pucek, W. F., Hoffmann, K., Bryl, W., Kus, K., & Paczkowska, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1906959
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
Pharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
王, 钰. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163787
Bartkowiak, D., Jakubczyk, B., Lasota, A., Kopoczyński, Ł., Wiesner, M., Wodzinski, L., Boguszewski, K., Porazinski, H., Mlynarska, A., & Ratajski, O. (2026) · Cureus · doi:10.7759/cureus.116245
Physiology and therapeutic insights of incretins in 2026: An update
Hirlemann, M., Phan, A., Carette, C., Beyec, J. L., Ledoux, S., & Gall, M. L. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.08.106
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
Kamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Khalil, I., Chatterjee, S., Dutta, D., Haq, T., Alanazi, M. A., & Pappachan, J. M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70181 · Cited by 1
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
The WHO Essential Medicines List can help to unlock access to GLP-1 therapies for metabolic syndrome
Pottie, K. C., Saluja, K., Dewidar, O., Saad, A., Hajizadeh, H., Moja, L., & Abidi, S. S. R. (2026) · Nature Health · doi:10.1038/s44360-026-00114-0 · Cited by 2
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
Mei, X., & Lu, D. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202625001013
Elatrebi, S. F., Abuyadek, R. M., Abdelbar, S. M. M., Ahmad, M. S., Ayyad, M., Quoritem, M. A., Majid, R. O. A., Arafat, M., Amgad, A., & Alnagar, A. (2026) · World Journal of Transplantation · doi:10.5500/wjt.120572
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
Kim, M., Choi, I., Kim, S.-J., Park, B., Lee, S., Park, K., Huh, J., & Hahn, S. K. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100491 · Cited by 1
A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies
Durma, A. C., & Czupryniak, L. (2026) · Nutrients · doi:10.3390/nu18162602 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Self-citationFuture Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Ahmed, M. M., Nazari, R., Othman, Z. K., Musa, S. S., Okesanya, O. J., Adebayo, U. O., Branda, F., Elmi, A. H., & Prisno, D. E. L. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261472587 · Cited by 2
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
RetractedAdipositas: neue medikamentöse Therapien
Seufert, J. (2026) · Nervenheilkunde · doi:10.1055/a-2939-1909
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Reappraising obesity management in the GLP-1 receptor agonist era
Christmas, T., Ahmed, A. R., & Tan, T. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00126-0
Keyserling, T. C., Wu, Q., Ammerman, A. S., Berkowitz, S. A., Buse, J. B., Couper, D. J., Evenson, K. R., Hursting, S., Sotres‐Alvarez, D., Lyons, K. M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29006 · Cited by 1
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
Management of Obstructive Sleep Apnea in People with Type 2 Diabetes
Patel, N., Soliman, M., Majithia, A. R., & Malhotra, A. (2026) · Diabetology · doi:10.3390/diabetology7070128
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Shinde, S., Kahles, F., Vasileva-Metodiev, S. Z., Griffin, R. M., Liu‐Seifert, H., Lebrec, J., Xavier, N., Li, R., Klise, S. R., Singh, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71322 · Cited by 1
Self-citationRethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
Cruz, P., Puebla-Huerta, A., Troncoso, M. F., Silva-Pavez, E., Hidalgo, Y., & Ahumada-Castro, U. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1826699
Klein, K. R., WYSHAM, C. H., Tuttle, K. R., Davies, M. J., Cox, D., Chen, J., Wu, W.-S., Denning, M., Liu, R., Ludwig, L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01865-9 · Cited by 3
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
Ihle‐Hansen, H., Ihle-Hansen, H., Blauenfeldt, R. A., Dawson, J., Diederichsen, S. Z., & Hagberg, G. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1918465
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Metadata
- Authors
- Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R.
- Affiliations
- York University (CA)
- Weill Cornell Medicine (US)
- Eli Lilly, Indianapolis
- King Fahd Medical City (SA)
- Universitat Autònoma de Barcelona (ES)
- Chiba University (JP)
- Obesity Center, Nove de Julho Hospital, São Paulo
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-11-06
- Volume
- 393
- Issue
- 18
- Pages
- 1796-1806
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4414222945
- Semantic Scholar
- 55f79ec956543eaa7356b0d7489de3768b213da0
- Cited by
- 189
- References
- 22
- Citations by year
- 2026: 177 · 2025: 12
- FWCI
- 106.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity treatment, weight loss, waist circumference, blood pressure, lipid profile, gastrointestinal adverse effects, drug safety, dose comparison, non-diabetic obesity, treatment discontinuation, serious adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Oxadiazoles, Weight Loss, Treatment Outcome, Fluorine Compounds, Anti-Obesity Agents, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.